Abbisko Advances KRAS G12D Cancer Program With First Patient Dosed in ABSK141 Trial

Abbisko Cayman Limited has announced the first patient dosing in a Phase I/II trial of ABSK141, a small-molecule inhibitor targeting KRAS G12D mutations in advanced solid tumors. This milestone, cleared by the U.S. FDA and China’s NMPA, positions Abbisko to compete in KRAS-targeted therapy, an area of significant industry focus. Preclinical data suggest ABSK141 may provide best-in-class oral bioavailability and anti-tumor activity. The current analyst rating for Abbisko Cayman Limited (HK:2256) is a Hold with a price target of HK$13.00.